Clinical trial
Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or…
NCT00356889 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00356889 |
|---|---|
| Title | Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors |
| Official title | A Phase II Trial of Bevacizumab and Erlotinib in Patients With Advanced Biliary Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Gastrointestinal Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer |
| Intervention type | Biological, Drug |
| Interventions | erlotinib hydrochloride, bevacizumab |
| Enrollment | 56 |
| Start date | May 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Jun 1, 2010 |
| First posted | Jul 27, 2006 |
| Last update posted | May 28, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: